

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOCARE

诺诚健华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9969)

INSIDE INFORMATION ANNOUNCEMENT

INNOCARE PHARMA LIMITED TO REGAIN GLOBAL RIGHTS TO ORELABRUTINIB FOLLOWING BIOGEN'S DECISION TO TERMINATE THE COLLABORATION AND LICENSE AGREEMENT

This announcement is made by InnoCare Pharma Limited (the “**Company**” or “**InnoCare**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Reference is made to the Company’s announcement dated 13 July 2021, in relation to the Agreement (as defined below) with Biogen.

The Company announced today that Biogen has notified the Company of its decision to terminate for convenience the Collaboration and License Agreement (the “**Agreement**”) between the parties for the global development and commercialization of orelabrutinib, an oral small molecule Bruton’s tyrosine kinase (BTK) inhibitor for the potential treatment of multiple sclerosis (MS) and other autoimmune diseases. Following the termination, InnoCare will regain all global rights granted to Biogen under the Agreement, including related intellectual property, decision-making regarding research and development, manufacturing, and commercialization, and commercial proceeds generated from orelabrutinib. The parties will collaborate to complete the transition within 90 days.

InnoCare welcomes orelabrutinib back to our autoimmune portfolio. The Phase II MS global study is ongoing and the Company expects to publish results from the interim analysis in the second quarter of 2023. Given the encouraging clinical outcomes from multiple autoimmune trials, the Company remains confident and committed to accelerating the global development of orelabrutinib as a potentially best-in-class BTK inhibitor for MS and other autoimmune diseases.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui

Chairperson and Executive Director

Hong Kong, 15 February 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi, Mr. Shan Fu, Mr. Ronggang Xie and Mr. Ming Jin as non-executive Directors, and Dr. Zemin Jason Zhang, Ms. Lan Hu and Dr. Kaixian Chen as independent non-executive Directors.